Aura Biosciences, Inc.
AURA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $73 | $64 | $42 | $25 |
| G&A Expenses | $23 | $20 | $18 | $10 |
| SG&A Expenses | $23 | $20 | $18 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $96 | $84 | $60 | $35 |
| Operating Income | -$96 | -$85 | -$60 | -$35 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $9 | $9 | $2 | -$0 |
| Pre-Tax Income | -$87 | -$76 | -$59 | -$35 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$87 | -$76 | -$59 | -$35 |
| % Margin | – | – | – | – |
| EPS | -1.75 | -1.93 | -1.96 | -1.58 |
| % Growth | 9.3% | 1.5% | -24.1% | – |
| EPS Diluted | -1.75 | -1.93 | -1.96 | -1.58 |
| Weighted Avg Shares Out | 50 | 40 | 30 | 29 |
| Weighted Avg Shares Out Dil | 50 | 40 | 30 | 29 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $9 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$95 | -$84 | -$59 | -$34 |
| % Margin | – | – | – | – |